CTT Pharmaceutical Holdings develops oral delivery technology designed to administer medications for pain relief. The company specializes in thin wafer formulations that dissolve quickly in the mouth and can contain cannabis-derived compounds as an alternative to traditional smoking or swallowing methods. Based in Tampa, Florida, its primary asset is a patented dissolvable strip system for oral medication delivery.
1Y: 0.05 (-29.5%) · range 0.04–0.10
entry readiness 81 · STRONG SETUP · exit proximity 0
Value area 0.06–0.08 · 92% of 97d volume overhead · heavy supply
CTTH is a sub-penny nanocap ($0.05) with a thin, internally conflicting dossier: the daily blend shows a strong technical setup (EMA/technical 81, readiness 81) but the absolute score disagrees hard (composite 37, technical leg 3, HOLD/NEUTRAL) and Markov puts an 87% chance of staying in a DOWN trend. The lone corroborating signal — a CEO insider buy — is a token $175, too small to carry weight. With no Monte Carlo on record and the daily lane itself only at WATCH (no confirmed trigger), there is not enough convergent, promoted evidence to justify a directional lean.
- Daily blend readiness 81 [STRONG SETUP] with EMA/technical leg at 81 and Buildup 68
- Pattern overlay shows double_bottom:forming, score 54 (NEUTRAL)
- Insider Activity source fired at 0.400 with a CEO on the form4 cluster
- Absolute score just 37/100, HOLD/NEUTRAL, with technical leg at 3 — contradicts the blend's 81 technical read
- Markov trend is DOWN with P(stay) 87%, and peer cluster is NEUTRAL
- The insider 'cluster' is 1 insider buying only $175 — economically negligible
- Daily lane is WATCH not OPEN (entry not confirmed); no Monte Carlo simulation on record; $0.05 tape is nanocap-thin coverage
Invalidated if: A confirmed breakout that flips the daily lane to OPEN and turns Markov trend UP would invalidate the neutral read; conversely a close below the double-bottom low confirms the downtrend.
| Source | Score | Last seen |
|---|---|---|
| insider-activity | 0.400 | Sep 11, 2026 |
Not yet labeled — the study prices these as positions mature.